Loading…
Arvinas, Inc. is projected to rise to $10.95 by 2027, a +24% move from its current price of $8.85. ARVN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $8.63 | $8.85 | $9.07 | +0.02% |
| May 30 | $8.55 | $8.85 | $9.17 | +0.03% |
| May 31 | $8.48 | $8.85 | $9.24 | +0.05% |
| Jun 1 | $8.43 | $8.86 | $9.31 | +0.06% |
| Jun 2 | $8.38 | $8.86 | $9.36 | +0.08% |
| Jun 3 | $8.33 | $8.86 | $9.41 | +0.09% |
| Jun 4 | $8.30 | $8.86 | $9.46 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.30 | $8.86 | $9.46 | +0.11% |
| Week 2 | $8.08 | $8.87 | $9.73 | +0.22% |
| Week 3 | $7.92 | $8.88 | $9.95 | +0.33% |
| Week 4 | $7.79 | $8.89 | $10.14 | +0.44% |
| Week 5 | $7.68 | $8.90 | $10.31 | +0.55% |
| Week 6 | $7.58 | $8.91 | $10.47 | +0.66% |
| Week 7 | $7.49 | $8.92 | $10.61 | +0.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. It develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. The company develops clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer.
In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG.
The company was founded in 2013 and is based in New Haven, Connecticut.
Arvinas, Inc. trades under the symbol ARVN and has a current price of $9.09 with a market capitalization of $586.5M. It is ranked 2925 by market size. The stock sits in a smaller biotech niche, with a 30-day price range from $7.65 to $10.80 and a current technical picture showing bearish sentiment with an RSI of 40.
The short-term technicals show the stock trading around important moving averages, with a SMA50 of $10.46 and a SMA200 of $10.60, and clearly defined support at $8.55 and resistance at $11.00.
A major floor 20.7% below — a decisive break under it would weaken the trend.
The nearest floor, 3.4% below — buyers have tended to step in here.
The nearest ceiling, 24.3% above — a clean break opens room to run.
A major ceiling 56.3% above — clearing it would confirm fresh momentum.
Key ARVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.01 | Sell | $8.97 | Sell |
| MA 10 | $9.08 | Sell | $9.14 | Sell |
| MA 20 | $9.61 | Sell | $9.51 | Sell |
| MA 50 | $10.33 | Sell | $10.32 | Sell |
| MA 100 | $11.54 | Sell | $10.81 | Sell |
| MA 200 | $10.63 | Sell | $11.25 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.69 | Neutral |
| Stoch RSI (14) | 51.45 | Neutral |
| CCI (20) | -89.90 | Neutral |
| Williams %R (14) | -81.71 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -12.46 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 18.29 | Buy |
| TRIX (15) | -0.63 | Sell |
| Awesome (5,34) | -1.05 | Sell |
| Ultimate (7,14,28) | 35.95 | Neutral |
| Momentum (10) | -0.72 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 8.99 | Sell |
| ADX (14) | 24.94 | Sell |
| ATR (14) | 0.22 | Info |
The 30-day technical picture is bearish, with an RSI14 of 40. The stock trades near the moving averages, with a SMA50 of $10.46 and a SMA200 of $10.60. Support sits at $8.55 and resistance at $11.00, framing a 30-day range of $7.65 to $10.80.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.55 | $8.85 | $11.58 | 0% | Neutral | |
| $8.76 | $10.95 | $14.46 | +24% | Bullish | |
| $8.28 | $10.60 | $14.47 | +20% | Neutral | |
| $8.12 | $10.61 | $14.87 | +20% | Neutral | |
| $8.61 | $11.47 | $16.42 | +30% | Bullish | |
| $8.49 | $11.49 | $16.78 | +30% | Bullish | |
| $9.97 | $13.71 | $20.36 | +55% | Bullish | |
| $11.06 | $15.42 | $23.28 | +74% | Bullish | |
| $10.85 | $15.34 | $23.50 | +73% | Bullish | |
| $11.57 | $16.57 | $25.72 | +87% | Bullish | |
| $15.17 | $23.05 | $37.90 | +160% | Bullish | |
| $21.58 | $36.28 | $64.89 | +310% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $8.55 | $8.85 | $10.43 | +0.00% |
| June 2026 | $7.79 | $9.14 | $10.95 | +3.24% |
| July 2026 | $7.60 | $8.98 | $10.89 | -1.74% |
| August 2026 | $7.46 | $8.86 | $10.86 | -1.27% |
| September 2026 | $7.59 | $9.07 | $11.19 | +2.31% |
| October 2026 | $7.61 | $9.12 | $11.34 | +0.60% |
| November 2026 | $7.47 | $8.99 | $11.25 | -1.43% |
| December 2026 | $7.62 | $9.21 | $11.58 | +2.40% |
Click any year to see its month-by-month ARVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ARVN to range from $8.55 to $11.58 through 2026. The $8.85 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ARVN price prediction for 2027 points to an average of $10.95 (low $8.76, high $14.46) — a potential gain of +24% on today's $8.85. Buyers look set to stay in control over this stretch.
In 2028, ARVN is projected to trade between $8.28 and $14.47, averaging $10.60 — a potential gain of +20% from today's $8.85. That is -3% versus the projected 2027 average. Price action looks broadly range-bound.
Arvinas, Inc.'s 2029 outlook centres on $10.61, within a $8.12 to $14.87 range. That is up 0% on the projected 2028 average. That marks a +20% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, ARVN could reach as high as $16.42, with a base case around $11.47 and support toward $8.61 — roughly +30% from $8.85. Momentum favours further upside here.
Expect ARVN to range from $8.49 to $16.78 through 2031. The $11.49 average target implies a +30% move from current prices. That is up 0% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ARVN price prediction for 2032 points to an average of $13.71 (low $9.97, high $20.36) — a potential gain of +55% on today's $8.85. Momentum favours further upside here.
In 2033, ARVN is projected to trade between $11.06 and $23.28, averaging $15.42 — a potential gain of +74% from today's $8.85. That is up +13% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Arvinas, Inc.'s 2034 outlook centres on $15.34, within a $10.85 to $23.50 range. That is -1% versus the projected 2033 average. That marks a +73% change versus current levels. Momentum favours further upside here.
By 2035, ARVN could reach as high as $25.72, with a base case around $16.57 and support toward $11.57 — roughly +87% from $8.85. Buyers look set to stay in control over this stretch.
Expect ARVN to range from $15.17 to $37.90 through 2040. The $23.05 average target implies a +160% move from current prices. That is up +39% on the projected 2035 average. Momentum favours further upside here.
The ARVN price prediction for 2050 points to an average of $36.28 (low $21.58, high $64.89) — a potential gain of +310% on today's $8.85. Buyers look set to stay in control over this stretch.
Investing $1,000 in ARVN today (≈ 112.99435 ARVN) could be worth
$4,099.31
+$3,099.31 (+310%) by 2050 · US Dollar
Based on the average projected ARVN price of $36.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARVNwould be worth at today's price.
$1,000 invested in ARVN on May 27, 2025 (≈ 149.47683 ARVN) would be worth
$1,322.87
+$322.87 (+32.3%) today · 1.32× · US Dollar
Based on a ARVN entry price of $6.69 vs. today's $8.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.1 | $972.53 | -2.7% |
| 1 month ago | $10.29 | $860.06 | -14.0% |
| 3 months ago | $13.38 | $661.43 | -33.9% |
| 6 months ago | $12.59 | $702.94 | -29.7% |
| 1 year ago | $6.69 | $1,322.87 | +32.3% |
| All time (5.0y) ago | $71.51 | $123.76 | -87.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARVN forecast.
Our base-case forecast reaches $18.00 around 2040.
Implied market cap at $18.00: $1.16B
The multi-year forecast is broadly bullish, with positive momentum from 2027 onward. The 2026 projection shows a min of $8.55, an avg of $9.09, and a max of $12.08, with a 0% ROI and neutral sentiment. In 2027, the avg rises to $11.34 and the max to $15.07, delivering a 24.7% ROI and bullish sentiment.
The 2028 forecast has an avg of $10.92 (min $8.47, max $15.02) with a 20.1% ROI and bullish sentiment, followed by 2029 with an avg of $11.00 and a 21% ROI. By 2030, the avg is $11.90 (min $8.86, max $17.22) and the ROI reaches 30.9% with bullish sentiment. The trajectory continues in 2031 (avg $11.92, ROI 31.1%), 2032 (min $10.40, avg $14.44, max $21.71, ROI 58.9%), 2033 (min $11.49, avg $16.21, max $24.77, ROI 78.3%), and 2034 (min $11.21, avg $16.05, max $24.90, ROI 76.6%).
By 2035 the avg is $17.48 with a 92.3% ROI, and by 2040 the avg jumps to $24.27 with a strong 167% ROI (min $15.70, max $40.54). The longer-range view shows 2050 with an avg of $38.77 and a max of $70.64, delivering a 326.5% ROI, all under bullish sentiment. These figures illustrate a generally rising path for ARVN with meaningful upside potential alongside inherent near-term uncertainty.
Tap a question to reveal the answer.
2030 forecast: min $8.86, avg $11.90, max $17.22, ROI 30.9%, sentiment BULLISH.
Forecasts show bullish sentiment in 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2040 and 2050 with rising avg prices; 2026 is neutral with ROI 0%. Example: 2027 avg $11.34 (ROI 24.7%), 2040 avg $24.27 (ROI 167%), 2050 avg $38.77 (ROI 326.5%).
Yes. The 2040 forecast shows a max of $40.54 with an average of $24.27 and a min of $15.70, sentiment BULLISH and ROI 167%.
Bearish sentiment with RSI14 at 40. The stock trades around SMA50 of $10.46 and SMA200 of $10.60, with support at $8.55 and resistance at $11.00. The 30-day price range is $7.65 to $10.80.
Current price is $9.09 and market cap is $586.5M; the stock is ranked 2925.
Arvinas, Inc. Community Discussion
0Share your Arvinas, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.